Skip to content
ChickenStockChickenStock
ResearchNTLA
Intellia Therapeutics logo

Intellia Therapeutics (NTLA) stock

NASDAQ

$9.70-8.06%(-0.85)

As of the Nov 13, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-3.18x

Net loss — not comparable

P/B

2.22x

P/S

25.62x

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue decreased 50.0% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 5, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

6 SEC filings
  • LEONARD JOHN MPresident and CEO · Nov 2, 2026Open-market sale9,000 shares · $108K
    Avg. price $11.991,138,064 shares held after
  • Marantz Jing L.EVP, Chief Medical Officer · Oct 26, 2026Grant or award199,822 shares · $0
    Avg. price $0199,822 shares held after
  • Dube Michael PVP, Chief Accounting Officer · Oct 2, 2026Open-market sale1,864 shares · $23K
    Avg. price $12.4365,022 shares held after
  • LEONARD JOHN MPresident and CEO · Aug 21, 2026Open-market sale2,785 shares · $36K
    Avg. price $131,147,064 shares held after
  • LEONARD JOHN MPresident and CEO · Aug 20, 2026Open-market sale19,890 shares · $251K
    Avg. price $12.61,149,849 shares held after
  • Dulac Edward J IIIEVP, Chief Financial Officer · Jul 22, 2026Open-market sale8,111 shares · $91K
    Avg. price $11.25148,175 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Intellia Therapeutics (NTLA) stock information

NASDAQ

Intellia Therapeutics (NTLA) is listed on NASDAQ. Its market capitalization is about $1.4B. On trailing-twelve-month earnings the P/E ratio is -3.18, and the P/B ratio is 2.22. Return on equity is -69.7%. These figures are computed in-house from official filings and are reference information only.

Intellia Therapeutics — frequently asked questions

What is the P/E ratio of Intellia Therapeutics (NTLA)?
On a trailing-twelve-month basis, NTLA trades at a P/E ratio of -3.18. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Intellia Therapeutics?
NTLA has a market capitalization of about $1.4B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.